Not exact matches
BMS's drug, ipilimumab (Yervoy), was the first
checkpoint inhibitor (a kind of cancer immunotherapy drug that essentially helps the
immune system release its brake and go
after tumor cells it might normally miss) to get approved in the US in 2011 for melanoma.
In recent years, though, discoveries have led to a new class of drugs called
checkpoint inhibitors, which have mobilized the
immune system to see and go
after cancer.
After progressing to BRAFi + MEKi and
immune -
checkpoint inhibitors, BRAFmutant metastatic melanoma patients have no alternative therapeutic options.
In the next year, members of the Dream Team will continue to study the tumor microenvironment before and
after checkpoint blockade, to develop algorithms to identify and predict the best antigens on cancer cells that can be used for cancer immunotherapies, to analyze tumor tissues and blood for biomarkers that will help in selecting patients who will benefit, and identifying the best approaches to increase the strength of
immune cells for adoptive cell therapy.